U.S. markets closed

Freeline Therapeutics Holdings plc (FRLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.9500-0.0600 (-1.50%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close4.0100
Open4.0200
Bid3.8100 x 3200
Ask4.0500 x 800
Day's Range3.8000 - 4.0200
52 Week Range2.9200 - 18.8800
Volume285,614
Avg. Volume460,384
Market Cap141.421M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.0590
Earnings DateAug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Freeline Therapeutics Holdings
    Daily – Vickers Top Buyers & Sellers for 05/25/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • GlobeNewswire

    Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease

    Clinical trial site initiation for Gaucher disease Type 1 on track by year endLONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that both the U.S. Food and Drug Administration (“FDA”) and European Commission (“EC”) have granted Orphan Drug Designa

  • GlobeNewswire

    Freeline to Participate in Upcoming Investor Conferences in September 2021

    LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that Chief Executive Officer Michael Parini is scheduled to present at the following virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, Fi

  • Simply Wall St.

    Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Deliver On Growth Plans?

    Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...